)
Visual
test
LeonaBio
LeonaBio (LONA) investor relations material
LeonaBio Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Mar, 2026
Executive summary
Acquired exclusive global license (excluding Asia and certain Middle East countries) for lasofoxifene, a late-stage SERM targeting metastatic breast cancer with ESR1 mutations.
Raised $90 million in private placement financing, with warrants potentially providing up to $146 million more to support clinical development.
Transitioned from Athira Pharma to LeonaBio, reflecting a strategic shift to a focused, diversified biopharma company with two clinical-stage programs.
Advanced lasofoxifene into a Phase 3 trial and ATH-1105 into Phase 1, with plans for a Phase 2 ALS study in 2H 2026.
Financial highlights
Cash, cash equivalents, and investments totaled $88.3 million as of December 31, 2025, up from $51.3 million at year-end 2024.
Net loss was $105.6 million ($24.70 per share) for 2025, compared to $96.9 million ($25.19 per share) in 2024.
R&D expenses rose to $85.6 million in 2025 from $70.7 million in 2024, mainly due to acquired in-process R&D for lasofoxifene.
G&A expenses decreased to $16.7 million in 2025 from $26.1 million in 2024, reflecting cost efficiencies.
Net cash used in operations was $45.7 million in 2025, down from $97.2 million in 2024.
Outlook and guidance
Enrollment for the Phase 3 ELAINE-3 trial of lasofoxifene expected to complete in 4Q 2026, with topline data anticipated in 2H 2027.
Phase 2 proof-of-concept study of ATH-1105 in ALS patients planned to initiate in 2H 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from LeonaBio
- All proposals, including key share issuances and governance changes, were approved by majority vote.LONA
EGM 202618 Mar 2026 - Proposal 6 is now routine, enabling discretionary broker voting at the March 2026 meeting.LONAProxy Filing10 Mar 2026
- Shareholders to vote on major share issuances, new equity plan, and increased authorized stock.LONAProxy Filing23 Feb 2026
- Shareholders to vote on key share issuances, new equity plan, and major charter amendment.LONAProxy Filing4 Feb 2026
- Exclusive lasofoxifene license and $236M financing drive late-stage cancer and ALS programs.LONAStatus Update3 Feb 2026
- Fosgonimeton is tested in a pivotal Alzheimer's trial using GST, with results due in 2H24.LONAStatus Update3 Feb 2026
- Pivotal Alzheimer's trial readout expected in fall, with strong cash position and ALS expansion planned.LONAGoldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026
- LIFT Alzheimer's trial nears data, with strong interim results and ALS program advancing.LONAJefferies 2024 Global Healthcare Conference1 Feb 2026
- Registering 5.5M shares for resale, proceeds to fund cancer and ALS drug development.LONARegistration Filing20 Jan 2026
Next LeonaBio earnings date
Q1 20268 May, 2026
LeonaBio
Next LeonaBio earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage